Traws Pharma Announces New Employee Inducement Grants
02 avr. 2024 07h15 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (Nasdaq: TRAW, “Traws”, the “Company”) today announced it has granted equity awards to new employees who joined Traws in...
Onconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology Company
02 avr. 2024 07h00 HE
|
Onconova Therapeutics, Inc.
Closing cash balance of approximately $28 million expected from concurrent private placement led by OrbiMed and Torrey PinesFunding expected to advance development of three potential...
Onconova Therapeutics’ Rigosertib Poster Selected for AACR 2024
08 mars 2024 08h00 HE
|
Onconova Therapeutics, Inc.
Onconova Therapeutics’ Rigosertib Poster Selected for AACR 2024
Onconova Therapeutics’ Narazaciclib ASH Poster Highlights Activity in Treatment Resistant Mantle Cell Lymphoma
12 déc. 2023 08h00 HE
|
Onconova Therapeutics, Inc.
Preclinical data show that narazaciclib treatment led to significant tumor growth inhibition, demonstrating synergy with standard-of-care ibrutinib, in ibrutinib-sensitive and -resistant settings ...
Onconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’s
08 déc. 2023 16h05 HE
|
Onconova Therapeutics, Inc.
Onconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’s
Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference
28 nov. 2023 08h00 HE
|
Onconova Therapeutics, Inc.
Onconova presenting at NobleCon19 Dec 4-5 in Boca Raton, FL
Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results
14 nov. 2023 16h05 HE
|
Onconova Therapeutics, Inc.
Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results
Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023
07 nov. 2023 16h05 HE
|
Onconova Therapeutics, Inc.
Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023
Onconova Therapeutics’ ASH Poster To Focus on Narazaciclib in MCL
02 nov. 2023 10h37 HE
|
Onconova Therapeutics, Inc.
Preclinical data indicate that narazaciclib shows monotherapy and combination anti-tumor activity in ibrutinib-sensitive and resistant cells and xenograft models NEWTOWN, Pa., Nov. 02, 2023 (GLOBE...
Onconova Expands Leadership Team with Two Key Appointments
24 oct. 2023 08h00 HE
|
Onconova Therapeutics, Inc.
Onconova Expands Leadership Team: Victor Moyo named Chief Medical Officer, Meena Arora joins as Vice President Global Medical Affairs and R&D